Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel potent fibrate analogues synthesized at Dr. Reddy's

April 7, 2006

Duramed withdraws Lo Seasonale NDA

April 7, 2006

Potent FXR antagonists from Amgen

April 7, 2006

New orally active progesterone receptor agonists presented by Wyeth

April 6, 2006

Orphan drug designation for EPI-A0001

April 6, 2006

Wyeth presents new orally active progesterone receptor antagonist

April 5, 2006

New agents for endocrine-related disorders imparted in recent patent literature

April 4, 2006

Myozyme approved for Pompe disease in Europe

April 4, 2006

Novel agents for metabolic disorders reported in recent patents

April 4, 2006

Takeda submits NDA for ACTOplus met XR

April 3, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
NTX-819, a novel mGlu7 NAM for psychiatric disorders
BioWorld Science
Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...